Document Code:	PMP_X129	Date of Issue:	25 th July 2024
Version Number:		2.2	

PD-L1 EXPRESSION TESTING PRIOR TO NIVOLUMAB THERAPY (DAKO PD-L1 IHC 28-8 pharmDx KIT)

PATIENT DETAILS									
SURNAME:		FORENAME:							
DOB:	SEX:	NHS No:							
HOSPITAL No:		ROUTINE:		URGENT:					

REFERRING CLINICIAN									
NAME:	HOSPITAL:								
EMAIL:	TEL:								
PLEASE TICK TO INDICATE INVOICING PREFERE	NCE:	PATHOLOGIST		PHYSICIAN					

SAMPLE / CLINICAL DETAILS		
PATHOLOGY HOSPITAL:		DATE SENT:
REPORT / PATHOLOGY No:	SPEC TYPE:	
KNOWN DECALCIFICAITON PROCESSES:		

SPE	CIMEN REQUIREMENTS	MOLECULAR CONTACT DETAILS			
• • •	Cytology samples are unsuitable for PD-L1 28-8 testing. Details of block requirement / section preparation can be found on our website: <u>qehbpathology.uk</u> Please supply copy of original Histopathology report. Residual material will be returned to you as soon as possible.	The Molecular Pathology Diagnostic Service Clinical Laboratory Services, Level -1 Queen Elizabeth Hospital – Birmingham, B15 2WB T : 0121 3713320 / 13325 E : <u>mpds.enguiries@nhs.net</u>			

			MP	DS OFFICE	USE				
DATE RVD:	RVD BY:					MATERIAL:			
BOOKED:	CHE	CHECKED:							
REG: ZP									
MPDS LABORATORY USE									
SECTIONING STAFF:					SEC	TIONING CH	ECK:		
	HE					HE ASSESSOR NAME:			
TUMOUR CONTENT:	1					HE ASSESSMENT DATE:			
TEST TYPE:	IHC		FISH			IDYLLA	DNA	۱.	RNA
CUTTING	x 3un	n	x 2um			5um	2 x 6um		10 x 6um
REQUIREMENTS:	x 4un	า				10um	3 x 6u	ım	8 x 6um
MACRODISSECTION:	YES		NO	SPECIA	L CUTI	TING INSTRU	CTIONS:		
SLIDES	SCR	OLLS							

CONTROLLED DOCUMENT	Approved by: Brendan O'Sullivan	Page 1 of 1